Eli Lilly Gets Full FDA Approval for Inluriyo in ESR1-Mutated Breast Cancer

The U.S. Food and Drug Administration (FDA) on Friday granted full approval to Eli Lilly and Co.’s (NYSE:LLY) Inluriyo (imlunestrant) in combination with Verzenio (abemaciclib) for pretreated breast cancer patients.

The approval covers estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2–), ESR1-mutated locally advanced or metastatic breast cancer (MBC), with disease progression following at least one line of endocrine therapy.

• Eli Lilly stock is trading at elevated levels. What’s ahead for LLY stock?

FDA Approval Backed by EMBER-3 Trial

The full FDA approval is based on the results of the Phase 3 EMBER-3 trial in patients with MBC whose tumors harbor an ESR1 mutation (n=159).

Among patients with ESR1-mutated MBC, Inluriyo in combination with Verzenio doubled median progression-free survival (PFS) versus Inluriyo alone, with a median PFS of 11.1 months versus 5.5 months.

Lilly continues to study Inluyiro in the ongoing Phase 3 EMBER-4 adjuvant trial, with initial results expected in 2027.

Financial Projections and Competitive Edge

In an investor note on Tuesday, TD Securities wrote, “From a competitive standpoint, Inluriyo has the advantage of being approved and leverages the well-established Verzenio franchise.”

Analyst Steve Scala said physicians will likely weigh efficacy gains against chronic CDK4-related toxicities, particularly diarrhea and neutropenia, which were common in EMBER-3 despite low discontinuation rates.

It remains uncertain whether physicians will use continuous ctDNA monitoring under AstraZeneca Plc’s (NYSE:AZN) Etcamah SERENA-6 protocol or wait for radiographic progression before initiating Inluriyo with or without Verzenio.

Lilly argues that switching both endocrine therapy and CDK4/6 inhibition at clinical progression could deliver better outcomes than earlier intervention.

However, direct comparisons between EMBER-3 and SERENA-6 are difficult because of differences in patient populations, treatment timing, and PFS measurement.

Future Opportunities

Scala sees the adjuvant breast cancer setting as the larger opportunity for oral SERDs, with giredestant awaiting approval and AstraZeneca and Eli Lilly awaiting readouts for their respective drugs.

TD Securities projects global Inluriyo sales of $290 million in 2026, rising to $1.05 billion by 2032.

LLY Price Action: Eli Lilly shares were up 0.32% at $1,168.60 at the time of publication on Tuesday, according to Benzinga Pro data.

Photo: Michael Vi / Shutterstock